Rezvilutamide (SHR-3680)
Revision as of 20:30, 17 June 2023 by Warner-admin (talk | contribs) (Text replacement - " (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT[0-9]{8})" to " [$1 Clinical Trials Registry]")
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. link to original article PubMed Clinical Trials Registry
Also known as
- Code name: SHR3680